Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Urine salts elucidate Early Neolithic animal management at Aşıklı Höyük, Turkey.

Abell JT, Quade J, Duru G, Mentzer SM, Stiner MC, Uzdurum M, Özbaşaran M.

Sci Adv. 2019 Apr 17;5(4):eaaw0038. doi: 10.1126/sciadv.aaw0038. eCollection 2019 Apr.

2.

Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study.

Berger AE, Duru G, de Vries A, Marini JC, Aoucheta D, Cornillie F, Nancey S, Detrez I, Gils A, Roblin X, Paul S.

Ther Drug Monit. 2019 Aug;41(4):459-466. doi: 10.1097/FTD.0000000000000629.

PMID:
30817702
3.

Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study.

Attar A, Duru G, Roblin X, Savarieau B, Brunel P, Lamure M, Peyrin-Biroulet L.

Dig Liver Dis. 2019 Jan;51(1):112-119. doi: 10.1016/j.dld.2018.08.029. Epub 2018 Sep 5.

PMID:
30268737
4.

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.

Amini-Adle M, Khanafer N, Le-Bouar M, Duru G, Dalle S, Thomas L.

BMC Cancer. 2018 Jul 3;18(1):705. doi: 10.1186/s12885-018-4618-9.

5.

Evaluation of large clinically atypical vulvar pigmentation with RCM: atypical melanosis or early melanoma?

Theillac C, Cinotti E, Malvehy J, Ronger Savle S, Balme B, Robinson P, Perrot JL, Douchet C, Biron Schneider AC, Alos L, Garcia A, Barreiro A, Labeille B, Duru G, Dalle S, Thomas L, Debarbieux S.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):84-92. doi: 10.1111/jdv.15141. Epub 2018 Jul 12.

PMID:
29920797
6.

Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?

Roblin X, Vérot C, Paul S, Duru G, Williet N, Boschetti G, Del Tedesco E, Peyrin-Biroulet L, Marc Phelip J, Nancey S, Flourie B.

Inflamm Bowel Dis. 2018 Apr 26. doi: 10.1093/ibd/izy111. [Epub ahead of print]

PMID:
29718216
8.

Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.

Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S.

Inflamm Bowel Dis. 2017 Nov;23(11):2048-2053. doi: 10.1097/MIB.0000000000001223.

PMID:
28945636
9.

Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.

Delaunay J, Martin L, Bressac-de Paillerets B, Duru G, Ingster O, Thomas L.

JAMA Dermatol. 2017 Nov 1;153(11):1122-1129. doi: 10.1001/jamadermatol.2017.2926.

10.

Dermoscopic Features of Subungual Squamous Cell Carcinoma: A Study of 44 Cases.

Teysseire S, Dalle S, Duru G, Phan A, Debarbieux S, Poulhalon N, Thomas L.

Dermatology. 2017;233(2-3):184-191. doi: 10.1159/000479059. Epub 2017 Aug 23.

11.

Surgical Treatment of Subungual Squamous Cell Carcinoma by Wide Excision of the Nail Unit and Skin Graft Reconstruction: An Evaluation of Treatment Efficiency and Outcomes.

Topin-Ruiz S, Surinach C, Dalle S, Duru G, Balme B, Thomas L.

JAMA Dermatol. 2017 May 1;153(5):442-448. doi: 10.1001/jamadermatol.2017.0014.

12.

Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.

Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S.

Inflamm Bowel Dis. 2017 Jan;23(1):126-132. doi: 10.1097/MIB.0000000000000986.

PMID:
28002129
13.

Motivations of patients seeking supportive care for cancer from physicians prescribing homeopathic or conventional medicines: results of an observational cross-sectional study.

Danno K, Colas A, Freyer G, Guastalla JP, Duru G, Musial E, Libourel V, Fendler JP, Masson JL, Bordet MF.

Homeopathy. 2016 Nov;105(4):289-298. doi: 10.1016/j.homp.2016.09.001. Epub 2016 Oct 24.

14.

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.

Teuma C, Perier-Muzet M, Pelletier S, Nouvier M, Amini-Adl M, Dijoud F, Duru G, Thomas L, Fouque D, Laville M, Dalle S.

Cancer Chemother Pharmacol. 2016 Aug;78(2):419-26. doi: 10.1007/s00280-016-3086-7. Epub 2016 Jul 1.

PMID:
27371224
15.

Homeopathic medical practice for anxiety and depression in primary care: the EPI3 cohort study.

Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Begaud B; EPI3-LA-SER group.

BMC Complement Altern Med. 2016 May 4;16:125. doi: 10.1186/s12906-016-1104-2.

16.

Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.

Faivre C, Villani AP, Aubin F, Lipsker D, Bottaro M, Cohen JD, Durupt F, Jeudy G, Sbidian E, Toussirot E, Badot V, Barbarot S, Debarbieux S, Delaporte E, Goegebeur G, Morel J, Nassif A, Duru G, Jullien D; French Society of Dermatology and Club Rheumatisms and Inflammation.

J Am Acad Dermatol. 2016 Jun;74(6):1153-9. doi: 10.1016/j.jaad.2016.01.018. Epub 2016 Mar 8.

PMID:
26965410
17.

Dermoscopy, a useful tool for general practitioners in melanoma screening: a nationwide survey.

Chappuis P, Duru G, Marchal O, Girier P, Dalle S, Thomas L.

Br J Dermatol. 2016 Oct;175(4):744-50. doi: 10.1111/bjd.14495. Epub 2016 Jun 30.

PMID:
26914613
18.

Economic impact of homeopathic practice in general medicine in France.

Colas A, Danno K, Tabar C, Ehreth J, Duru G.

Health Econ Rev. 2015 Dec;5(1):55. doi: 10.1186/s13561-015-0055-5. Epub 2015 Jul 8.

19.

Utilization of psychotropic drugs by patients consulting for sleeping disorders in homeopathic and conventional primary care settings: the EPI3 cohort study.

Grimaldi-Bensouda L, Abenhaim L, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Begaud B; EPI3-LA-SER Group.

Homeopathy. 2015 Jul;104(3):170-5. doi: 10.1016/j.homp.2015.05.002. Epub 2015 Jun 10.

PMID:
26143449
20.

Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument.

Beresniak A, Auray JP, Duru G, Aractingi S, Krueger GG, Talarico S, Tsutani K, Dupont D, de Linares Y.

J Cosmet Dermatol. 2015 Sep;14(3):260-5. doi: 10.1111/jocd.12156. Epub 2015 Jul 2.

PMID:
26133392
21.

Dermoscopic Features of Onychomatricoma: A Study of 34 Cases.

Lesort C, Debarbieux S, Duru G, Dalle S, Poulhalon N, Thomas L.

Dermatology. 2015;231(2):177-83. doi: 10.1159/000431315. Epub 2015 Jun 20.

PMID:
26111574
22.

The value of childhood combination vaccines: From beliefs to evidence.

Maman K, Zöllner Y, Greco D, Duru G, Sendyona S, Remy V.

Hum Vaccin Immunother. 2015;11(9):2132-41. doi: 10.1080/21645515.2015.1044180. Review.

23.

Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL instrument.

Beresniak A, Auray JP, Duru G, Aractingi S, Krueger GG, Talarico S, Adam AS, Piot B, Dupont D, de Linares Y.

J Cosmet Laser Ther. 2015;17(6):313-7. doi: 10.3109/14764172.2015.1039034. Epub 2015 Jul 2.

PMID:
25968164
24.

Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.

Roblin X, Attar A, Lamure M, Savarieau B, Brunel P, Duru G, Peyrin-Biroulet L.

J Mark Access Health Policy. 2015 Oct 30;3. doi: 10.3402/jmahp.v3.29229. eCollection 2015.

25.

Management of the early symptoms of influenza-like illnesses and ear, nose and throat (ENT) disorders by pharmacists.

Danno K, Cognet-Dementhon B, Thevenard G, Duru G, Allaert FA, Bordet MF.

Homeopathy. 2014 Oct;103(4):239-49. doi: 10.1016/j.homp.2014.04.001. Epub 2014 Jun 10.

PMID:
25439040
26.

Cost Effectiveness of Quadrivalent Influenza Vaccine Over Trivalent Vaccine in France.

Duru G, Carrat F, Pribil C, Bricaire F, Pujol P, Robert J, Lafuma A.

Value Health. 2014 Nov;17(7):A678. doi: 10.1016/j.jval.2014.08.2525. Epub 2014 Oct 26. No abstract available.

27.

Physician practicing preferences for conventional or homeopathic medicines in elderly subjects with musculoskeletal disorders in the EPI3-MSD cohort.

Danno K, Joubert C, Duru G, Vetel JM.

Clin Epidemiol. 2014 Sep 26;6:333-41. doi: 10.2147/CLEP.S64049. eCollection 2014.

28.

Comparison of NITAG policies and working processes in selected developed countries.

Ricciardi GW, Toumi M, Weil-Olivier C, Ruitenberg EJ, Dankó D, Duru G, Picazo J, Zöllner Y, Poland G, Drummond M.

Vaccine. 2015 Jan 1;33(1):3-11. doi: 10.1016/j.vaccine.2014.09.023. Epub 2014 Sep 23.

29.

Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.

Beresniak A, Medina-Lara A, Auray JP, De Wever A, Praet JC, Tarricone R, Torbica A, Dupont D, Lamure M, Duru G.

Pharmacoeconomics. 2015 Jan;33(1):61-9. doi: 10.1007/s40273-014-0216-0.

PMID:
25230587
30.

A forager-herder trade-off, from broad-spectrum hunting to sheep management at Aşıklı Höyük, Turkey.

Stiner MC, Buitenhuis H, Duru G, Kuhn SL, Mentzer SM, Munro ND, Pöllath N, Quade J, Tsartsidou G, Özbaşaran M.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8404-9. doi: 10.1073/pnas.1322723111. Epub 2014 Apr 28.

31.

Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder.

Bakkour N, Samp J, Akhras K, El Hammi E, Soussi I, Zahra F, Duru G, Kooli A, Toumi M.

Psychiatry Res. 2014 May 30;216(3):291-302. doi: 10.1016/j.psychres.2014.02.014. Epub 2014 Mar 3. Review.

PMID:
24656516
32.

Management of upper respiratory tract infections by different medical practices, including homeopathy, and consumption of antibiotics in primary care: the EPI3 cohort study in France 2007-2008.

Grimaldi-Bensouda L, Bégaud B, Rossignol M, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Abenhaim L, Guillemot D.

PLoS One. 2014 Mar 19;9(3):e89990. doi: 10.1371/journal.pone.0089990. eCollection 2014.

33.

Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients.

Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L, Dalac S, Delattre C, Déchelotte P, Courville P, Carlotti A, De Muret A, Fraitag S, Levy A, Mitchell A, Petrella T.

Am J Surg Pathol. 2014 May;38(5):673-80. doi: 10.1097/PAS.0000000000000156.

PMID:
24441662
34.

[Influenza, influenza-like illness: from theory to practice].

Carrat F, Avouac B, Cedraschi C, Duru G, Greppo G, Libourel V, Vancells J, Vétel JM.

Presse Med. 2014 Mar;43(3):240-6. doi: 10.1016/j.lpm.2013.09.004. Epub 2014 Jan 17. French.

PMID:
24440768
35.

Characteristics of patients consulting their regular primary care physician according to their prescribing preferences for homeopathy and complementary medicine.

Lert F, Grimaldi-Bensouda L, Rouillon F, Massol J, Guillemot D, Avouac B, Duru G, Magnier AM, Rossignol M, Abenhaim L, Begaud B; EPI3-LA-SER Group.

Homeopathy. 2014 Jan;103(1):51-7. doi: 10.1016/j.homp.2013.09.001.

PMID:
24439455
36.

Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

Perier-Muzet M, Thomas L, Poulalhon N, Debarbieux S, Bringuier PP, Duru G, Depaepe L, Balme B, Dalle S.

J Invest Dermatol. 2014 May;134(5):1351-1358. doi: 10.1038/jid.2013.462. Epub 2013 Nov 7.

37.

[Contracts including performance and management of uncertainty].

Duru G, Garassus P, Auray JP.

Ann Pharm Fr. 2013 Sep;71(5):338-45. doi: 10.1016/j.pharma.2013.08.008. Epub 2013 Sep 5. French.

PMID:
24075704
38.
39.

Overview of the use of dermoscopy in academic and non-academic hospital centres in France: a nationwide survey.

Breton AL, Amini-Adle M, Duru G, Poulalhon N, Dalle S, Thomas L.

J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1207-13. doi: 10.1111/jdv.12260. Epub 2013 Sep 3.

PMID:
23998395
40.

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):393-406. doi: 10.1586/erp.13.19. Epub 2013 Mar 28.

PMID:
23537397
41.

Who seeks primary care for sleep, anxiety and depressive disorders from physicians prescribing homeopathic and other complementary medicine? Results from the EPI3 population survey.

Grimaldi-Bensouda L, Engel P, Massol J, Guillemot D, Avouac B, Duru G, Lert F, Magnier AM, Rossignol M, Rouillon F, Abenhaim L, Begaud B; EPI3-LA-SER group.

BMJ Open. 2012 Nov 22;2(6). pii: e001498. doi: 10.1136/bmjopen-2012-001498. Print 2012.

42.

Validation of a new international quality-of-life instrument specific to cosmetics and physical appearance: BeautyQoL questionnaire.

Beresniak A, de Linares Y, Krueger GG, Talarico S, Tsutani K, Duru G, Berger G.

Arch Dermatol. 2012 Nov;148(11):1275-82. doi: 10.1001/archdermatol.2012.2696.

PMID:
23165832
43.

Relationships between black tea consumption and key health indicators in the world: an ecological study.

Beresniak A, Duru G, Berger G, Bremond-Gignac D.

BMJ Open. 2012 Nov 8;2. pii: e000648. doi: 10.1136/bmjopen-2011-000648. Print 2012.

44.

Dermoscopy use by French private practice dermatologists: a nationwide survey.

Moulin C, Poulalhon N, Duru G, Debarbieux S, Dalle S, Thomas L.

Br J Dermatol. 2013 Jan;168(1):74-9. doi: 10.1111/j.1365-2133.2012.11216.x. Epub 2012 Dec 17.

PMID:
22880932
45.

Impact of physician preferences for homeopathic or conventional medicines on patients with musculoskeletal disorders: results from the EPI3-MSD cohort.

Rossignol M, Begaud B, Engel P, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L; EPI3-LA-SER group.

Pharmacoepidemiol Drug Saf. 2012 Oct;21(10):1093-101. doi: 10.1002/pds.3316. Epub 2012 Jul 11.

PMID:
22782803
46.

Clinical and economic impact of malnutrition per se on the postoperative course of colorectal cancer patients.

Melchior JC, Préaud E, Carles J, Brami M, Duru G, Fontaine E, Hébuterne X, Lukacs B, Zazzo JF, Panis Y, Nitenberg G.

Clin Nutr. 2012 Dec;31(6):896-902. doi: 10.1016/j.clnu.2012.03.011. Epub 2012 May 19. Erratum in: Clin Nutr. 2014 Oct;33(5):927. Multiple author names corrected.

PMID:
22608918
47.

Benchmarking the burden of 100 diseases: results of a nationwide representative survey within general practices.

Grimaldi-Bensouda L, Begaud B, Lert F, Rouillon F, Massol J, Guillemot D, Avouac B, Duru G, Magnier AM, Rossignol M, Abenhaim L; EPI3-LA-SER Group.

BMJ Open. 2011 Nov 14;1(2):e000215. doi: 10.1136/bmjopen-2011-000215. Print 2011.

48.

Benchmarking clinical management of spinal and non-spinal disorders using quality of life: results from the EPI3-LASER survey in primary care.

Rossignol M, Begaud B, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L.

Eur Spine J. 2011 Dec;20(12):2210-6. doi: 10.1007/s00586-011-1780-z. Epub 2011 Apr 13.

49.

Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review.

Lantéri-Minet M, Duru G, Mudge M, Cottrell S.

Cephalalgia. 2011 May;31(7):837-50. doi: 10.1177/0333102411398400. Epub 2011 Apr 4. Review.

PMID:
21464078
50.

Who seeks primary care for musculoskeletal disorders (MSDs) with physicians prescribing homeopathic and other complementary medicine? Results from the EPI3-LASER survey in France.

Rossignol M, Bégaud B, Avouac B, Lert F, Rouillon F, Bénichou J, Massol J, Duru G, Magnier AM, Guillemot D, Grimaldi-Bensouda L, Abenhaim L.

BMC Musculoskelet Disord. 2011 Jan 19;12:21. doi: 10.1186/1471-2474-12-21.

Supplemental Content

Support Center